Gilead Sciences (GILD) Analysis

This report is auto-generated by an AI stock research platform for informational purposes only. The content is for general information and research reference, and does not constitute financial advice. Data may lag or be incomplete. Always conduct your own research and consult qualified professionals before making any financial decisions. # [Qiltrack AI] Gilead Sciences, Inc. (GILD) 3-Minute Overview --- ### 🎯 Layer 1: 30-Second Key Takeaways > **💡 One-Sentence Summary** > > Gilead is the company that basically owns the HIV treatment market — they make the drugs that keep millions of people alive and healthy, and they're now trying to repeat that magic in cancer and liver disease. > **📍 Basic Profile** > > Market Cap **$163.0 billion** · Biotechnology · NASDAQ · Price **$131.28** --- > **⚡ 3 Things You Should Know** > > 1. 💊 **Cash Cow Machine**: Gilead's HIV franchise is a money printer — 79% gross margins and 42% ROE mean they turn every dollar of sales into serious profit without needing to reinvest heavily. This is a high-quality earnings engine, not a hype story. > > 2. 📉 **Growth Is a Question Mark**: Revenue growth over the past 3 years has been only 2.6% annually — this is a mature, slow-growing giant. The market is now waiting to see if new drugs (especially in cancer, like Trodelvy) can reignite growth, or if Gilead becomes "big but stagnant." > > 3. 💰 **Cheap-ish with a Catch**: At 17.5x earnings, Gilead trades below the typical biotech multiple, and the 2.5% dividend yield gives you a reason to wait. But insiders have been selling shares recently — not a huge red flag, but worth noting when you're deciding whether the value is real. --- > **🎯 Quick Health Check** > > | Dimension | Rating | Details | > |-----------|--------|---------| > | Profitability | Strong💪 | Net margin 31%, gross margin 79% — elite-level earnings power | > | Growth Rate | Slow🐢 | Revenue growth ~2.6% over 3 years, but EPS growing 23% | > | Financial Health | Healthy💚 | Current ratio 1.97, interest coverage 44.7x — very safe | > | Valuation | Fair | PE 17.5x, below biotech average, near 52-week low zone | --- ### 📋 Layer 2: 2-Minute Deep Dive #### 📊 How Does This Company Make Money? **Business Model in One Sentence:** Gilead discovers and sells antiviral drugs (especially for HIV) to governments, insurers, and patients worldwide, making money through recurring prescription sales and, increasingly, through cancer therapies. **Revenue Breakdown:** > ⚠️ *Note: Specific revenue segment data is not available in the dataset. Based on industry knowledge, the company's main segments are HIV (roughly 60-70% of sales), oncology, and liver disease.* **Profitability Metrics:** | Metric | Value | Ranking | Interpretation | |--------|-------|---------|----------------| | Gross Margin | 79.4% | Top 5% of all industries | Extremely high — typical of drug companies with patent-protected products | | Net Margin | 31.0% | Top 10% | For every $100 of sales, $31 becomes profit — very impressive | | ROE | 42.2% | Excellent (>20% is great) | Management is incredibly efficient at generating returns on shareholder money | --- #### 📈 How's the Growth? **Growth Assessment:** Slow Revenue Growth, but Strong Profit Growth | Metric | Latest | vs Last Year | Trend | |--------|--------|--------------|-------| | Revenue Growth (3Y) | 2.6% | — | Slow but positive | | EPS Growth (3Y) | 23.1% | — | Strong — profits growing much faster than sales | **Growth Quality:** > This is the interesting part. Revenue is barely growing (2.6%), yet earnings per share are growing 23% per year. How? Through cost control, share buybacks, and operational efficiency. The company is getting leaner and more profitable even without big sales growth. That's a sign of disciplined management, but it also means the "easy wins" from cost-cutting may eventually run out — future growth will need to come from new drugs. --- #### 💰 Financial Health Check **One Sentence:** Like a person who owns their house outright, has a stable government job, and a solid emergency fund — no financial stress here. | Metric | Value | Safe Zone | Assessment | |--------|-------|-----------|------------| | Debt-to-Equity | 1.10 | <1.5 acceptable for pharma | ✅ Safe — manageable leverage | | Current Ratio | 1.97 | >1.5 healthy | ✅ Safe — plenty of short-term liquidity | | Interest Coverage | 44.7x | >5x safe | ✅ Very Safe — 44x earnings cover interest costs, massive cushion | | Cash Flow/Share | $6.68 | Positive | ✅ Strong — generates real cash, not just paper profits | --- #### 🏷️ Is It Expensive Now? **Price Position (based on 52-week range):** - 52-Week Low: $108.46 - 52-Week High: $157.29 - Current: $131.28 | Position Range | Cheap Zone | Fair Zone | Pricey Zone | |----------------|------------|-----------|-------------| | Criteria | 0-33% | 33-66% | 66-100% | | **Current** | **●(41% position)** | | | **Valuation Comparison:** | Comparison | Current | Reference | Assessment | |------------|---------|-----------|------------| | vs Own History | PE 17.5x | Biotech sector avg ~20-25x | **Below** sector average — not expensive | | vs Peers | PE 17.5x | Large pharma avg ~15-18x | **In line** with large pharma peers | **What the Current Valuation is Betting On:** > At 17.5x earnings, the market is NOT betting on explosive growth. It's pricing Gilead as a mature, stable dividend payer — similar to a utility company but with better margins. The upside scenario is if Trodelvy (cancer drug) and new HIV treatments (like lenacapavir) surprise to the upside. The downside scenario is if the HIV franchise faces generic competition or pricing pressure. --- #### 📰 Any Recent News? | Date | Event | Impact | |------|-------|--------| | Jul 2026 | European regulators issued positive opinion for Trodelvy + Keytruda combo in advanced breast cancer | 🟢 Positive — expands cancer drug market opportunity | | Jul 2026 | Gilead to present new HIV data (lenacapavir) and Merck regimen at AIDS 2026 | 🟢 Positive — reinforces HIV leadership | | Jul 2026 | Stock lapped the market with +2.91% single-day gain | 🟢 Positive — short-term momentum | | Jul 2026 | Analysts expect Q2 earnings to decline | 🟡 Neutral — market already aware | | Jul 2026 | Multiple insider sales by executives | 🔴 Negative — insiders trimming positions | --- ### 📊 Layer 3: Want More? 3-Minute Complete Analysis #### I. Detailed Financial Data **Profitability Trends:** | Metric | Latest | Reference | Interpretation | |--------|--------|-----------|--------------| | Gross Margin | 79.4% | Very high | Stable, patent-protected pricing power | | Net Margin | 31.0% | Top tier | Excellent cost control | | ROE | 42.2% | Excellent | Superior capital allocation | > ⚠️ *Note: Historical 3-year trend data for margins is not available in this dataset.* **Growth Trends:** | Metric | Value | Interpretation | |--------|-------|--------------| | Revenue Growth (3Y CAGR) | 2.6% | Slow, mature business | | Revenue Growth (5Y CAGR) | 3.6% | Consistently slow | | EPS Growth (3Y CAGR) | 23.1% | Strong profit growth via efficiency | | EPS Growth (5Y CAGR) | 133.6% | Extraordinary — likely includes one-time effects | --- #### II. Earnings Track Record **Last 4 Quarters vs Expectations:** | Quarter | EPS Expected | EPS Actual | Surprise | |---------|--------------|------------|----------| | Q1 2026 | $1.95 | $2.03 | +4.0% Beat 😀 | | Q4 2025 | $1.85 | $1.86 | +0.7% Beat 😀 | | Q3 2025 | $2.17 | $2.47 | +13.7% Beat 😀 | | Q2 2025 | $2.00 | $2.01 | +0.6% Beat 😀 | **Earnings Trend Interpretation:** Gilead has beaten expectations 4 quarters in a row, with an impressive 13.7% beat in Q3 2025. This suggests management is conservative with guidance, or the business is performing better than Wall Street models. Consistent beats build credibility — this is a positive signal. --- #### III. What the Market Thinks **Analyst Ratings:** | Rating | Count | Percentage | |--------|-------|------------| | Strong Buy | 10 | 27% | | Buy | 20 | 54% | | Hold | 7 | 19% | | Sell | 0 | 0% | **Target Price:** Not available in dataset — but with 81% of analysts at Buy or Strong Buy and zero Sells, the street is clearly bullish. **Insider Activity:** Net **selling** in past 3 months — executives including the CEO (O'Day) and CFO (Dickinson) have been selling shares. > 💡 **What this means:** Insider selling is common for compensation diversification — it's not always a red flag. But when multiple top executives sell consistently, it's worth keeping an eye on. It doesn't negate the bullish analyst view, but it does add a note of caution. --- #### IV. Key Risk Alerts **3 Risks to Watch:** 1. **⚠️ HIV Franchise Concentration**: Gilead's revenue is heavily dependent on HIV drugs. If a competitor launches a better or cheaper treatment, or if pricing pressure increases, revenue could take a hit. → Watch for: generic competition announcements, pricing policy changes. 2. **⚠️ Pipeline Execution Risk**: The future growth story depends on Trodelvy and new HIV treatments (lenacapavir). If clinical trials fail or regulatory approvals are delayed, growth expectations would need to be revised downward. → Watch for: clinical trial results, FDA decisions. 3. **⚠️ Growth Stagnation**: With revenue growing only ~2.6% annually, Gilead risks becoming a "bond proxy" rather than a growth stock. If EPS growth slows (cost cuts run their course) and the dividend doesn't grow fast enough, the stock could lose its appeal. → Watch for: quarterly revenue growth, dividend growth announcements. --- ### 🎬 Summary & Next Steps > **📝 Three-Sentence Summary** > > **What it is:** Gilead is a biotech giant that dominates the HIV treatment market, generates massive cash flow, and pays a solid 2.5% dividend. > > **Key strength:** Elite profitability (42% ROE, 79% gross margins) and a fortress balance sheet — this is a high-quality business with predictable cash flows. > > **Key risk:** Growth is slow (2.6% revenue CAGR) and the stock's future depends on pipeline success in cancer and next-gen HIV treatments. Insiders selling also adds a hint of caution. --- > **🔍 Want to Learn More?** > > • Want to know if Gilead's moat in HIV is truly unbreakable? → Try【Buffett Mode】for deeper competitive analysis > > • Want to check for hidden landmines in the pipeline or patent cliffs? → Try【Muddy Mode】for risk screening > > • Is this a value trap or a hidden gem? Want to stress-test the growth assumptions? → Try【Musk Mode】for analysis